Biotech AltPep scores around $53m in Series B funding round
US-based amyloid diseases treatment solutions developer AltPep has raised $52.9m in its Series B investment round led by Senator Investment Group.
US-based amyloid diseases treatment solutions developer AltPep has raised $52.9m in its Series B investment round led by Senator Investment Group.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Marinus Pharmaceuticals’ ZTALMY (ganaxolone) oral suspension.
Denmark-based biotech firm Tetra Pharm Technologies has introduced its first product in Germany.
Clinical-stage biotechnology company QurAlis has closed $88m in oversubscribed Series B financing round to advance precision medicines for neurodegenerative diseases.
Avenue Therapeutics has signed an exclusive license agreement with Taiwanese clinical-stage drug company AnnJi Pharmaceutical to develop and commercialise the first-in-class clinical asset, AJ201.
Coya Therapeutics has expanded its exclusive global licensing agreement with ARScience Biotherapeutics for low-dose IL-2 subcutaneous administration product candidate COYA 301.
The US Food and Drug Administration (FDA) has accepted a new drug application (NDA) filing by Biogen and Sage Therapeutics for their investigational drug zuranolone to treat major depressive disorder (MDD) and postpartum depression (PPD).
Rewind Therapeutics has raised further funding that has seen Sunstone Life Science Ventures joining as a new investor.
Forge Biologics has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) for its drug candidate FBX-101 to treat patients with Krabbe disease.
Myrtelle and rAAVen Therapeutics have announced a partnership to develop novel recombinant adeno-associated virus (rAAV) vectors to progress gene therapy treatments for diseases of the central nervous system (CNS) in which myelin is impacted.